Medrogestone

Medrogestone
Clinical data
Trade names	Colprone, others
Other names	Metrogestone; Medrogesterone; AY-62022, NSC-123018, R-13615; 6,17α-Dimethyl-6-dehydroprogesterone; 6,17α-Dimethyl-4,6-pregnadiene-3,20-dione
Pregnancy; category	X;
Routes of; administration	By mouth
Drug class	Progestogen; Progestin
ATC code	G03DB03 (WHO) ; G03FB07 (WHO) (with estrogen);
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	Nearly 100%
Protein binding	95%: Albumin (90%), CBGTooltip corticosteroid-binding globulin (3%), SHBGTooltip sex hormone-binding globulin (2%)
Metabolism	Hepatic (hydroxylation)
Elimination half-life	35–36 hours
Identifiers
	IUPAC name (8R,9S,10R,13S,14S,17S)-17-acetyl-6,10,13,17-tetramethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one;
CAS Number	977-79-7;
PubChem CID	9949848;
DrugBank	DB09124;
ChemSpider	8125459;
UNII	077DN93G5B;
KEGG	D04885;
CompTox Dashboard (EPA)	DTXSID70878637 ;
ECHA InfoCard	100.012.323
Chemical and physical data
Formula	C23H32O2
Molar mass	340.507 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C4\C=C3\C(=C/[C@@H]1[C@H](CC[C@@]2([C@@](C(=O)C)(CC[C@@H]12)C)C)[C@@]3(C)CC4)C;
	InChI InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1; Key:HCFSGRMEEXUOSS-JXEXPEPMSA-N;

Medrogestone, sold under the brand name Colprone among others, is a progestin medication which has been used in menopausal hormone therapy and in the treatment of gynecological disorders. It is available both alone and in combination with an estrogen. It is taken by mouth.

Medrogestone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has weak antiandrogenic, glucocorticoid, and antimineralocorticoid activity and no other important hormonal activity. Due to its progestogenic activity, medrogestone has antigonadotropic effects.

Medrogestone was described as early as 1963 and was introduced for medical use by at least 1966. It has mostly been discontinued and remains available only in a few countries.